SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

October 19, 2012 12:20 ET

Implant Sciences to Exhibit at Transport Security Expo in London

WILMINGTON, MA--(Marketwire - Oct 19, 2012) -  Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it will present its Quantum Sniffer™ trace detection technologies at the Transport Security Expo in London, England on November 14 and 15. Both the handheld Quantum Sniffer QS-H150 explosives trace detector and the Quantum Sniffer QS-B220 desktop explosives and drugs trace detectors will be presented to potential customers at booth D37.

For the past 10 years, Transport Security Expo has been a leading event for global heads of aviation, maritime, counter piracy, public transport and supply chain security. Designed to deliver clarity to the complex task of protecting passengers, cargo and high risk assets from those intent on doing harm, the Transport Security Expo describes itself as the world's most established event in this arena.

"Implant Sciences has seen growing interest in the QS-B220, particularly with aviation security and air cargo professionals. As we look to expand our market presence and grow our revenues, participation in shows like this will help us reach new customers and new distributors," stated Implant Sciences President and CEO Glenn D. Bolduc.

"Transport Security Expo provides an excellent venue for showing our products, which are in use today in many of the market segments targeted by the show, including airports, subways, ports, and cargo facilities. Our participation in this event will support the efforts of our growing network of distributors throughout Europe, the Middle East and Africa. We look forward to presenting our products to the international group of key security experts from aviation, maritime, and public transportation that will be present at the Expo," added Dr. Darryl Jones, Implant Sciences Vice President of Global Sales and Marketing.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact